AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man

Exploratory Clinical Investigation to evaluate the feasibility and safety of the AblaView® Unipolar Percutaneous Ablation Irrigated Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation using Polarization Sensitive Optical Coherence Reflectometry (PS-OCR) to guide delivery of Pulsed Field Ablation (PFA) lesions - First in Man

Study Overview

• Status: Completed
• Conditions: Paroxysmal AF
• Intervention / Treatment: Device: AblaView® Unipolar PFA System

Detailed Description

Exploratory Clinical Investigation to evaluate the feasibility and safety of the AblaView® Unipolar Percutaneous Ablation Irrigated Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation using Polarization Sensitive Optical Coherence Reflectometry (PS-OCR) to guide delivery of Pulsed Field Ablation (PFA) lesions - First in Man

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Uzbekistan
  • Tashkent, Uzbekistan
    • Ezgu Niyat

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

A subject will be eligible for study participation if he/she meets the following criteria:

1. Symptomatic Paroxysmal Atrial Fibrillation (PAF) with at least one documented episode in the 6 previous months (according to the ESC 2020 guidelines and AHA/ACC 2023 Guidelines). Documentation may include ECG, trans-telephonic monitor (TTM), Holter monitor (HM), or telemetry strips.
2. Eligible for de novo catheter intra-atrial ablation (e.g., pulmonary vein isolation).
3. Eligible for Transesophageal echocardiography (TEE) or Intracardiac Echocardiography (ICE) (AHA/ACC/HRS 2014 Guidelines for AF Management pertaining to anticoagulation at the time of cardioversion and the update in 2023) performed within 24 hours of the ablation procedure in all patients with AF of 48 hours duration or of unknown duration if adequate systemic anticoagulation has not been maintained for at least 1 month prior to AF ablation.
4. Antero-posterior left atrial diameter ≤ 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 3 months prior to the procedure.
5. Age ≥ 18 years and ≤ 85 years on the day of enrollment.
6. Voluntarily accepts participation after being duly informed of the ablation procedure and its risks, as well as the remapping procedure planned three months later, by signing the informed consent form.

Exclusion Criteria:

1. Persistent or long-standing persistent AF.
2. Arrhythmia due to reversible causes, including thyroid disorders, acute alcohol intoxication, electrolyte disorders, and other major surgical procedures in the preceding three months.
3. Myocardial infarction (MI), acute coronary syndrome percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within the preceding 3 months.
4. Antero-posterior Left atrial diameter > 5.5 cm
5. Previous left atrial ablation procedures, either surgical or catheter ablation.
6. Prior left atrial intervention, surgical procedure, or incision with resulting scar, including AF ablation or LAA closure.
7. Previous tricuspid or mitral valve replacement or repair.
8. Presence of an implantable cardiac defibrillator (ICD).
9. Heart disease for which corrective surgery is anticipated within 6 months.
10. Active systemic infection.
11. Bleeding diathesis or suspected procoagulant state.
12. Contraindication to long-term antithromboembolic therapy.
13. Presence of a condition that precludes appropriate vascular access.
14. Estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m2 or has ever received dialysis renal failure requiring dialysis.
15. Body mass index > 40.
16. Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with premedication.
17. Contraindication to general anesthesia (GA)
18. Contraindications to computed tomography.
19. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms.
20. Positive pregnancy test results for female subjects with childbearing potential.
21. Has known pulmonary vein stenosis, or other anatomic or concomitant conditions that, in the investigator's opinion, could limit the subject's ability to participate in the study, comply with follow-up requirements, or impact the scientific soundness of the study results.
22. In the opinion of the Principal Investigator (PI), it is unlikely to survive the clinical investigation plan with a follow-up period of twelve months.
23. Clinically significant psychological conditions that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.
24. Currently participating in another clinical investigation or participating in a clinical investigation that may interfere with this clinical investigation within 30 days prior to screening.
25. Severely compromised LVEF (LVEF <40%)
26. The presence of intracardiac thrombus (e.g., LA), myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.
27. Severe mitral regurgitation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Device Feasibility
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Patients treated under PFA; Single-Arm study, all patients included will undergo PFA using AblaView® Unipolar PFA System

Device: AblaView® Unipolar PFA System; Patients with symptomatic paroxysmal atrial fibrillation will be treated with the AblaView® Unipolar PFA System system to achieve electrical isolation of the pulmonary veins. The AblaView® Unipolar PFA Catheter is a regular PFA irrigated catheter. The tip of the catheter has 7 holes distributed around that deliver at the same time irrigation and near infrared light for the OCR system, which will be processed and interpreted by the Console.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Acute	Serious procedure- and device-related adverse events. Serious adverse events, and their relatedness to the AblaView Unipolar PFA System or procedure will be adjudicated by the Clinical Events Committee. The sites are required to report all adverse events.	Up to 3 months
Realtime predictability of PFA ablation lesion chronicity	Feasibility: 3-month Validation: Predictability Assessment by PS-OCR and PFA Lesions continuity and chronicity at 3-month remapping. Evaluation of the predictability of chronicity of ablation lesions in terms of Accuracy, Specificity and Sensitivity	Up to 3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Procedure Parameters	Skin-to-skin procedural time, minutes; Device left atrial dwell time, minutes; Time between first and last application, minutes; Fluoroscopy time during procedure, minutes; Total amount of PFA energy delivered in, joules.; Number of applications per targeted vein and/or isolation and for complete procedure, number	The day of the procedure
Procedure Validation	Acute Validation (20 to 30) min at least after the completion of each line/isolation by Electrical and optical isolation of targeted pulmonary veins (PVs), yes or no	The day of the procedure
Recurrence	Recurrence or new occurrence of arrhythmias controlled by Holter 48-hrs and by TTM weekly and triggered by symptoms.	Up to 3 months
Safety at 1 month	MACE (30d)	At 1 month
Safety at 3 months	Occurence of Atrial/Ventricular Arrhythmias, Stroke, HF	Between 1 month and 3 months
Per procedure (Ablation/remapping) optical parameters	Detection of optical signals to evaluate contact and birefringence in the left atria, yes or no; Detection and quantification of changes in birefringence during ablation, in %; Detection of gaps in the continuous ablation/isolation lines during ablation procedure, yes or no	The day of procedure
Improvement in the Quality of Life	Atrial Fibrillation Effect on Quality-of-Life (AFEQT) score difference between baseline and at 3 month; European Quality of Life-5 Dimensions (EQ-5D-5L) score difference between baseline and at 3 month in total and for mobility, self-care, usual activities, pain/discomfort and anxiety/depression	At 3 months

Collaborators and Investigators

• Sponsor: Medlumics
• Collaborators: Clinical Accelerator
• Investigators: Study Chair: Atul Verma, MD, PhD, Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; Study Chair: Raphael Martins, MD, PhD, University of Rennes, CHU Rennes, Rennes, France; Principal Investigator: Askar Sabirov, MD, Cardiology Department, AKFA Medline University Hospital, Tashkent, Uzbekistan; Study Chair: Giorgi Papiashvili, MD, PhD, Israeli-Georgian Medical Research Clinic Healthycore and European University, Tbilisi; Georgia.

Study record dates

Study Major Dates

• Study Start (Actual): September 8, 2024
• Primary Completion (Actual): December 20, 2024
• Study Completion (Actual): February 28, 2025

Study Registration Dates

• First Submitted: November 14, 2024
• First Submitted That Met QC Criteria: November 19, 2024
• First Posted (Actual): November 21, 2024

Study Record Updates

• Last Update Posted (Actual): March 28, 2025
• Last Update Submitted That Met QC Criteria: March 25, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Atrial Fibrillation; PFA; Optically guided
• Other Study ID Numbers: 48437

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Small feasibility studies of device products

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No